Rocket


Overview
Financials
News + Filings
IR Vault
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results
Appointed director
CC transcript
Inv. presentation

VIVUS INC (VVUS) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/13/2020 GN VIVUS Seeks Bankruptcy Court Approval of Second Amended Joint Chapter 11 Plan of Reorganization and Existing Stock Record Date
07/07/2020 GN VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLC
06/02/2020 GN VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P.
05/01/2020 GN VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Wednesday, May 6, 2020
05/01/2020 GN VIVUS Announces Agreement with IEH Biopharma LLC Granting the Company a 30-Day Grace Period to Restructure its Corporate Debt
04/03/2020 GN VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
04/01/2020 GN VIVUS Announces $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules
03/31/2020 GN VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Social Distancing”
02/19/2020 GN VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream
02/18/2020 GN VIVUS to Host Fourth Quarter Business Update and Financial Results Conference Call on Tuesday, March 3, 2020
01/07/2020 GN New Data Further Demonstrate Effectiveness of VIVUS' Qsymia as a Weight Management Tool
01/02/2020 GN VIVUS to Present at Biotech Showcase on January 13, 2020
12/31/2019 GN VIVUS Adopts Stockholder Rights Plan
12/18/2019 GN VIVUS Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity
11/25/2019 GN VIVUS to Present at Piper Jaffray 31st Annual Healthcare Conference on December 3, 2019
11/20/2019 GN New Clinical Data Demonstrate VIVUS' Qsymia® is Effective at Reducing Binge Eating in Patients with Binge-Eating Disorder or Bulimia Nervosa
10/21/2019 GN VIVUS to Highlight Integrated Approach to More Effective Weight Management in Panel Discussion at the Cleveland Clinic 2019 Medical Innovation Summit
08/28/2019 GN VIVUS to Present at Upcoming Conferences
08/27/2019 GN VIVUS to Share Qsymia® Safety and Efficacy Data with a Global Audience at ICOMES & AOCO 2019
08/20/2019 GN New Pilot Clinical Study Results Demonstrate that Addition of VIVUS' Qsymia® to Gastric Sleeve Surgery Significantly Improves Weight Loss Compared with Surgery Alone
08/06/2019 GN VIVUS Reports Second Quarter 2019 Financial Results
07/23/2019 GN VIVUS to Host Second Quarter Business Update and Financial Results Conference Call on Tuesday, August 6, 2019
06/26/2019 GN VIVUS and Nordmark Amend Contract Manufacturing Agreement to Supply Current and Future Demand for PANCREAZE®
06/11/2019 GN VIVUS Reduces Barrier to Achieving Healthy Weight Goals With Launch of Online Platform to Purchase Qsymia®
05/28/2019 GN VIVUS Initiates Phase Four Safety and Efficacy Study of Qsymia® in Obese Adolescents
05/15/2019 GN VIVUS Partners with HarborPath Direct to Facilitate Access to PANCREAZE® for Patients Without Health Insurance
04/16/2019 GN VIVUS to Host First Quarter Business Update and Financial Results Conference Call on Tuesday, April 30, 2019
02/26/2019 GN VIVUS Reports Fourth Quarter 2018 Financial Results
02/13/2019 GN VIVUS to Host Fourth Quarter and Full Year Business Update and Financial Results Conference Call on Tuesday, February 26, 2019
12/27/2018 GN VIVUS to Present at Biotech Showcase on January 9, 2019
11/01/2018 GN VIVUS Reports Third Quarter 2018 Financial Results
10/29/2018 GN VIVUS Adds Two New Members to the Board of Directors
10/26/2018 GN VIVUS to Host Third Quarter Business Update and Financial Results Conference Call on Thursday, November 1, 2018
10/10/2018 GN VIVUS to Present at the BIO Investor Forum on October 17, 2018
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy